Bloomberg the Company

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Follow Us

Industry Products

  • Exchange: London
  • Sector: Health Care
  • Industry: Health Care Facilities & Svcs
  • Sub-Industry: Health Care Services

INS:LN

155.500 GBp 0.0000.00%

As of 11:35:21 ET on 01/28/2015.

Snapshot for Instem PLC (INS)

Open: 155.500 Day's Range: 155.500 - 155.500 Volume: 0
Previous Close: 155.500 52wk Range: 123.500 - 197.500 1-Yr Rtn: -9.59%

Stock Chart for INS

No chart data available.
  • INS:LN 155.500
  • 1D
  • 1M
  • 1Y
155.500
Interactive INS Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for INS

Current P/E Ratio (ttm) 335.8531
Estimated P/E(12/2014) 19.1975
Relative P/E vs. UKX 17.8731
Earnings Per Share (GBP) (ttm) 0.0046
Est. EPS (GBP) (12/2014) 0.0810
Est. PEG Ratio -
Market Cap (M GBP) 18.66
Shares Outstanding (M) 12.00
30 Day Average Volume 20,915
Price/Book (mrq) 4.1406
Price/Sale (ttm) 1.5925
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 03/31/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for INS

  • Revenue
  • Net Income (M/GBP)
  • Profit Margin (%)

Company Profile & Key Executives for INS

Instem PLC provides information technology applications to the global early development healthcare market. The Group is focused on the early development sector of the drug and chemical research and development industry, from late discovery and lead optimisation through to the Phase I clinical evaluation stage.

Philip John Reason "Phil"Chief Executive OfficerNigel J GoldsmithCFO/Secretary
More Company Profile & Key Executives for INS

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil